DeutschNewstral
Article
Iinvezz.com on 2021-08-03 19:22
Eli Lilly CEO explains why profit missed estimates in fiscal Q2
Related news
- IRestaurant Brands CEO explains why revenue missed estimates in Q3invezz.com
- IEli Lilly CEO defends earnings miss in fiscal Q3invezz.com
- IEli Lilly Q2 results: its Alzheimer’s drug could be ‘the biggest drug in history’invezz.com
- BEli Lilly Earnings Beats Estimates. It Also Raised Its Sales Forecast.1 min readbarrons.com
- MBiogen, Eli Lilly earnings beats push industry stocks upmarketwatch.com
- BEli Lilly Stock Rises as Earnings Guidance Beats Analyst Expectationsbarrons.com
- HEli Lilly to Trim Workforce by Nearly 9 Percenthamodia.com
Eli Lilly ends drug development, stock plungesUSA today- MWalmart (WMT) earnings Q2 2022 beat estimatesmvtelegraph.com
- MSew Repair (SFIX) Q2 2021 earnings estimatesmvtelegraph.com
- MEli Lilly tops profit estimates in latest quarter as revenue falls shortmarketwatch.com
- MEli Lilly shares fall 2% premarket as 2016 outlook lags estimatesmarketwatch.com
- IEli Lilly beats Q4 estimates on solid demand for weight-loss druginvezz.com
- IAlphabet blows out Street estimates in Q2 on strong advertising salesinvezz.com
- IEli Lilly shares edge higher despite Q2 earnings miss: should you buy or sell LLY?invezz.com
- BEli Lilly Stock Falls as Sales Disappoint. Analyst Welcomes Diabetes Data.barrons.com
- IPaychex tops Wall Street estimates for profit and revenue in fiscal Q2invezz.com
Slipping COVID-19 treatment demand hits Eli Lilly forecastSeattle Times- IBiogen vs Eli Lilly: Jim Cramer weighs ininvezz.com
- IEli Lilly Q1 results: ‘Russia isn’t a big part of our portfolio’invezz.com